Skip to main content

Animations

MJFF Publications

8781 - 8790 of 9145 Results
Title
Year
  • Year
  • 2022
  • 2025
  • 2025
  • 2021
  • 2024
  • 2025
  • 2023
  • 2024
  • 2024
  • 2024
  • Summary Details
    OPEN
    Title: Mapping dopaminergic projections in the human brain with resting-state fMRI
    Journal Name: eLife
    Publisher: eLife Sciences Publications, Ltd
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.7554/elife.71846
    Citation Count: 41
  • Summary Details
    OPEN
    Title: Brain age prediction and early neurodegeneration detection using contrastive learning on brain biomechanics: a retrospective, multicentre study
    Journal Name: eBioMedicine
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by, cc-by
    DOI - Digital Object Identifier: 10.1016/j.ebiom.2025.105996
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Baseline α-synuclein seeding activity and disease progression in sporadic and genetic Parkinson's disease in the PPMI cohort
    Journal Name: eBioMedicine
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.ebiom.2025.105866
    Citation Count: 5
  • Summary Details
    OPEN
    Title: An integrated genomic approach to dissect the genetic landscape regulating the cell-to-cell transfer of α-synuclein
    Journal Name: Cell Reports
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd, cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.celrep.2021.109189
    Citation Count: 13
  • Summary Details
    OPEN
    Title: Open-source platform for kinematic analysis of mouse forelimb movement
    Journal Name: STAR Protocols
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.xpro.2024.103140
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Quantitative 3D histochemistry reveals region-specific amyloid-β reduction by the antidiabetic drug netoglitazone
    Journal Name: PLOS One
    Publisher: Public Library of Science (PLoS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc0
    DOI - Digital Object Identifier: 10.1371/journal.pone.0309489
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(23)00109-6
    Citation Count: 702
  • Summary Details
    OPEN
    Title: RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1016/s1474-4422(24)00121-2
    Citation Count: 110
  • Summary Details
    OPEN
    Title: MAPT H2 haplotype and risk of Pick's disease in the Pick's disease International Consortium: a genetic association study
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1016/s1474-4422(24)00083-8
    Citation Count: 23
  • Summary Details
    OPEN
    Title: The LRRK2 kinase substrates RAB8a and RAB10 contribute complementary but distinct disease-relevant phenotypes in human neurons
    Journal Name: Stem Cell Reports
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.stemcr.2024.01.001
    Citation Count: 15
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.